Watch MRK. Know when insiders buy.
One email the day a filing lands. Free.
MRK
Merck & Co., Inc.
149.88
+1.58 +1.07%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
2
FLAG · shorts 2
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
2 / 1
buys / sells · latest disclosed Oct 7
Big money
3 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $369.8BP/E 119.0DIV YIELD 2.24%FCF YIELD 4.34%REV TTM $66.6B +4.6%NET INCOME $3.2B −80.7%NET DEBT $11.3B52W 82.49 – 156.45SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $16.6B | +5.1% | 73.5% | — | −$1.3B | −130.2% | -0.54 | $5.4B | $893M | $4.5B | Aug 7 |
| Q1 2026 · Mar 31 | $16.3B | +4.9% | 74.2% | — | −$4.2B | −183.5% | -1.72 | $3.9B | $991M | $2.9B | May 4 |
| Q4 2025 · Dec 31derived | $16.4B | +5.0% | 66.2% | — | $3B | −20.8% | 1.20 | $2.9B | $1B | $1.8B | Feb 24 |
| Q3 2025 · Sep 30 | $17.3B | +3.7% | 77.7% | — | $5.8B | +83.2% | 2.32 | $7.8B | $987M | $6.8B | Nov 5 |
| Q2 2025 · Jun 30 | $15.8B | −1.9% | 77.5% | — | $4.4B | −18.8% | 1.76 | $3.3B | $764M | $2.5B | Aug 7 |
| Q1 2025 · Mar 31 | $15.5B | −1.6% | 78.0% | — | $5.1B | +6.7% | 2.01 | $2.5B | $1.3B | $1.2B | May 4 |
| Q4 2024 · Dec 31derived | $15.6B | +6.8% | 75.5% | — | $3.7B | — | 1.48 | $3.5B | $937M | $2.5B | Feb 24 |
| Q3 2024 · Sep 30 | $16.7B | +4.4% | 75.5% | — | $3.2B | −33.5% | 1.24 | $9.3B | $783M | $8.5B | Nov 5 |
| Q2 2024 · Jun 30 | $16.1B | — | 76.8% | — | $5.5B | — | 2.14 | $5.6B | $791M | $4.8B | Aug 5 |
| Q1 2024 · Mar 31 | $15.8B | — | 77.6% | — | $4.8B | — | 1.87 | $3.1B | $861M | $2.2B | May 2 |
| Q4 2023 · Dec 31derived | $14.6B | — | 73.3% | — | −$1.2B | — | -0.48 | $246M | $989M | −$743M | Feb 24 |
| Q3 2023 · Sep 30 | $16B | — | 73.3% | — | $4.7B | — | 1.86 | $7.7B | $902M | $6.8B | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $65B | 74.8% | — | $18.3B | 28.1% | 7.28 | $16.5B | $4.1B | $12.4B | $5.1B | $8.2B |
| FY2024 · to Dec 31 | $64.2B | 76.3% | — | $17.1B | 26.7% | 6.74 | $21.5B | $3.4B | $18.1B | $1.3B | $7.8B |
| FY2023 · to Dec 31 | $60.1B | 73.2% | — | $365M | 0.6% | 0.14 | $13B | $3.9B | $9.1B | $1.3B | $7.4B |
| FY2022 · to Dec 31 | $59.3B | 70.6% | — | $14.5B | 24.5% | 5.71 | $19.1B | $4.4B | $14.7B | $0 | $7B |
| FY2021 · to Dec 31 | $48.7B | 72.0% | — | $13B | 26.8% | 5.14 | $13.1B | $4.4B | $8.7B | $840M | $6.6B |
| FY2020 · to Dec 31 | $41.5B | 67.2% | — | $7.1B | 17.0% | 2.78 | $10.3B | $4.4B | $5.8B | $1.3B | $6.2B |
Every number comes from Merck & Co., Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.